Continuing EGFR-TKI beyond radiological progression in patients with advanced or recurrent, EGFR mutation-positive non-small-cell lung cancer: an observational study
| Autor: | Yoshiaki Mori, Kiyotaka Yoh, Young Hak Kim, Hiroshi Isobe, Terufumi Kato, Makoto Nishio, Hideo Kunitoh, Yoshio Tomizawa, Yukio Hosomi, Koichi Minato, Yasuo Ohashi, Yasushi Goto, Hiroshi Sakai, Yoshinori Hasegawa, Kazuhiko Yamada, Akira Inoue, Takayuki Kaburagi, Chiharu Tanai |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty beyond radiological progression 03 medical and health sciences 0302 clinical medicine Internal medicine tyrosine kinase inhibitors Medicine Epidermal growth factor receptor Lung cancer Original Research biology Performance status business.industry medicine.disease respiratory tract diseases Discontinuation Surgery 030104 developmental biology non-small-cell lung cancer Response Evaluation Criteria in Solid Tumors 030220 oncology & carcinogenesis Radiological weapon Cohort biology.protein epidermal growth factor receptor business Progressive disease |
| Zdroj: | ESMO Open |
| ISSN: | 2059-7029 |
| DOI: | 10.1136/esmoopen-2017-000214 |
| Popis: | Background Some patients with advanced or recurrent, epidermal growth factor receptor (EGFR) mutation-positive (EGFR M+) non-small-cell lung cancer (NSCLC) continue to receive EGFR tyrosine kinase inhibitors (TKIs) beyond radiological progression. Methods We analysed a cohort of 577 patients with EGFR M+ NSCLC, who had received a first-line EGFR-TKI. We classified patients according to clinical course and treatment patterns at Response Evaluation Criteria in Solid Tumors (RECIST) progressive disease (PD). We evaluated the period from RECIST PD to TKI discontinuation or clinical PD and also evaluated survival after RECIST PD and compared it between groups. Results RECIST PD was documented in 451 cases, of which 283 (62.7%) were clinically stable. 186 (65.7%) discontinued and 97 (34.3%) continued the EGFR-TKI. In those who continued EGFR-TKI, median time between RECIST PD and clinical PD or TKI discontinuation was 5.1 months. Median survival after RECIST PD in patients who discontinued and continued EGFR-TKI after clinically stable RECIST PD was 14.6 and 15.3 months (p=0.5489), respectively. In multivariate analysis, continuing EGFR-TKI therapy, female gender, better performance status and exon 19 deletion subtype were likely positive predictive factors for survival after clinically stable RECIST PD. Conclusion Our study suggests that some patients could benefit from receiving an EGFR-TKI beyond radiological progression. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|